Quantitative analysis of tumor vascular targeting: Effects of endostatin in a phase I clinical trial.

被引：0
|
作者：
Davis, DW
Mullani, N
Hess, KR
Tseng, J
O'Reilly, M
Herbst, RS
Abbruzzese, JL
McConkey, DJ
机构：
[1] MD Anderson Canc Ctr, Houston, TX USA
[2] Univ Texas, Sch Med, Houston, TX USA
来源：
CLINICAL CANCER RESEARCH | 2001年 / 7卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
286
引用
收藏
页码：3711S / 3711S
页数：1
相关论文
共 50 条
  • [1] An application of a factorial design to a phase I clinical trial.
    Carr, A
    Montague, TH
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P64 - P64
  • [2] Targeting signal transducer and activator of transcription 3 protein with arsenic trioxide A phase I clinical trial.
    Wetzler, M
    Brady, MT
    Donohue, KA
    Lee, SH
    Tighe, SM
    Ford, LA
    Wang, ES
    Baer, MR
    Baumann, H
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 569S - 569S
  • [3] Tissue examination to monitor antiangiogenic therapy: A phase I clinical trial with endostatin
    Mundhenke, C
    Thomas, JP
    Wilding, G
    Lee, FT
    Kelzc, F
    Chappell, R
    Neider, R
    Sebree, LA
    Friedl, A
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3366 - 3374
  • [4] Reality testing in cancer treatment: The phase I trial of endostatin
    Ryan, DP
    Penson, RT
    Ahmed, S
    Chabner, BA
    Lynch, TJ
    ONCOLOGIST, 2002, 7 : 58 - 65
  • [5] Hospitalizations in solid tumor phase I clinical trial patients: Incidence, pattern and clinical outcomes at an Australian phase I clinical trial unit
    Ye, Linda
    Ariyapperuma, Mihitha
    Jacques, Angela
    Meniawy, Tarek
    Millward, Michael
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2022, 18 (03) : 287 - 294
  • [6] EphA2 gene targeting using neutral liposomal small interfering RNA (EPHARNA) delivery: A phase I clinical trial.
    Naing, Aung
    Lopez-Berestein, Gabriel
    Fu, Siqing
    Tsimberidou, Apostolia Maria
    Pant, Shubham
    Piha-Paul, Sarina Anne
    Janku, Filip
    Hong, David S.
    Sulovic, Selma
    Meng, Xialong
    Jazaeri, Amir A.
    Ng, Chaan S.
    Karp, Daniel D.
    Subbiah, Vivek
    Meric-Bernstam, Funda
    Mitra, Rahul
    Wu, Sherry
    Sood, Anil
    Coleman, Robert L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [7] Pharmacokinetic and pharmacodynamic evaluation of RH1 during a phase I clinical trial.
    Ward, TH
    Danson, S
    Dawson, M
    McGrath, H
    Denneny, O
    Cummings, J
    Dive, C
    Ranson, M
    BRITISH JOURNAL OF CANCER, 2004, 91 : S60 - S60
  • [8] Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial.
    Sebastian, M.
    von Boehmer, L.
    Zippelius, A.
    Mayer, F.
    Reck, M.
    Atanackovic, D.
    Thomas, M.
    Schneller, F.
    Stoehlmacher, J.
    Goekkurt, E.
    Bernhard, H.
    Groeschel, A.
    Bals, R.
    Schmidt, S.
    Scheel, B.
    Koch, S. D.
    Lander, T.
    Kallen, K.
    Knuth, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [9] Phase I clinical trial of recombinant human endostatin administered as a short intravenous infusion repeated daily
    Eder, JP
    Supko, JG
    Clark, JW
    Puchalski, TA
    Garcia-Carbonero, R
    Ryan, DP
    Shulman, LN
    Proper, J
    Kirvan, M
    Rattner, B
    Connors, S
    Keogan, MT
    Janicek, MJ
    Fogler, WE
    Schnipper, L
    Kinchla, N
    Sidor, C
    Phillips, E
    Folkman, J
    Kufe, DW
    JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (18) : 3772 - 3784
  • [10] Phase I Clinical Trial of Vinorelbine in Tumor-Bearing Cats
    Pierro, J. A.
    Mallett, C. L.
    Saba, C. F.
    JOURNAL OF VETERINARY INTERNAL MEDICINE, 2013, 27 (04) : 943 - 948
12345